Items where authors include "Brown, J.E."

Article

McNaught, E., Reale, S., Bourke, L. et al. (14 more authors) (2024) Supported exercise training for men wIth prostate cancer on androgen deprivation therapy (STAMINA): study protocol for a randomised controlled trial of the clinical and cost-effectiveness of the STAMINA lifestyle intervention compared with optimised usual care, including internal pilot and parallel process evaluation. Trials, 25 (1). 257. ISSN 1745-6215

Moamin, M.R., Allen, R. orcid.org/0000-0003-2448-7987, Woods, S.L. et al. (4 more authors) (2023) Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse. Frontiers in Immunology, 14. 1291643. ISSN 1664-3224

Saleh, L., Ottewell, P.D. orcid.org/0000-0002-4826-0771, Brown, J.E. orcid.org/0000-0003-4960-3032 et al. (6 more authors) (2023) The CDK4/6 inhibitor palbociclib inhibits estrogen-positive and triple negative breast cancer bone metastasis in vivo. Cancers, 15 (8). 2211. ISSN 2072-6694

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Kwan, A., Howard, F. orcid.org/0000-0001-9899-3079, Winder, N. et al. (13 more authors) (2022) Macrophage delivered HSV1716 is active against triple negative breast cancer. Future Pharmacology, 2 (4). pp. 444-459. ISSN 2673-9879

Andrews, R.E., Brown, J.E. orcid.org/0000-0003-4960-3032, Lawson, M.A. orcid.org/0000-0002-5446-923X et al. (1 more author) (2021) Myeloma bone disease : the osteoblast in the spotlight. Journal of Clinical Medicine, 10 (17). 3973.

Brown, J.E. orcid.org/0000-0003-4960-3032, Wood, S.L., Confavreux, C. et al. (13 more authors) (2021) Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic : an international perspective and recommendations. Journal of Bone Oncology, 29. 100375. ISSN 2212-1374

Zhong, J., Palkhi, E., Buckley, D.L. et al. (7 more authors) (2021) Feasibility study on using dynamic contrast enhanced MRI to assess the effect of tyrosine kinase inhibitor therapy within the STAR trial of metastatic renal cell cancer. Diagnostics, 11 (7). 1302. ISSN 2075-4418

Brown, J.E., Handforth, C., Compston, J.E. et al. (13 more authors) (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 25. 100311. ISSN 2212-1374

Brown, J.E., Westbrook, J.A. and Wood, S.L. (2019) Dedicator of cytokinesis 4 : a potential prognostic and predictive biomarker within the metastatic spread of breast cancer to bone. Cancer Informatics, 18. pp. 1-3.

Rossi, S.H., Fielding, A., Blick, C. et al. (3 more authors) (2019) Setting research priorities in partnership with patients to provide patient-centred urological cancer care. European Urology, 75 (6). pp. 891-893. ISSN 0302-2838

Tulotta, C., Lefley, D.V., Freeman, K. et al. (16 more authors) (2019) Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment. Clinical Cancer Research, 25 (9). pp. 2769-2782. ISSN 1078-0432

Coleman, R.E., Collinson, M., Gregory, W. et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). JOURNAL OF BONE ONCOLOGY, 13. pp. 123-135. ISSN 2212-1374

Probert, C., Dottorini, T., Speakman, A. et al. (6 more authors) (2018) Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. ISSN 0950-9232

Ubellacker, J.M., Baryawno, N., Severe, N. et al. (13 more authors) (2018) Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer. Cancer Research , 78 (18). ISSN 0008-5472

Handforth, C. orcid.org/0000-0001-5171-4917, Burkinshaw, R., Freeman, J. et al. (4 more authors) (2018) Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Supportive Care in Cancer.

Zekri, J., Marples, M., Taylor, D. et al. (3 more authors) (2017) Complications of bone metastases from malignant melanoma. Journal of Bone Oncology, 8. pp. 13-17. ISSN 2212-1374

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096

Powles, T., Lackner, M.R., Oudard, S. et al. (18 more authors) (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 34 (14). 1660-U204. ISSN 0732-183X

Westbrook, J.A., Cairns, D.A., Peng, J. et al. (10 more authors) (2016) CAPG and gipc1: Breast cancer biomarkers for bone metastasis development and treatment. Journal of the National Cancer Institute, 108 (4). ISSN 0027-8874

Stopeck, A.T., Fizazi, K., Body, J.J. et al. (16 more authors) (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Supportive Care in Cancer, 24 (1). pp. 447-455. ISSN 0941-4355

Lipton, A., Fizazi, K., Stopeck, A.T. et al. (12 more authors) (2016) Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. EUROPEAN JOURNAL OF CANCER, 53. pp. 75-83. ISSN 0959-8049

Coleman, R.E. orcid.org/0000-0002-4275-1043, Lipton, A., Costa, L. et al. (9 more authors) (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2 (2). pp. 70-76. ISSN 2212-1366

Lester, J.E., Dodwell, D., Brown, J.E. et al. (6 more authors) (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. Journal of Bone Oncology, 1 (2). pp. 57-62. ISSN 2212-1374

Greenfield, D.M., Wright, J., Brown, J.E. et al. (6 more authors) (2006) High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening. British Journal of Cancer, 94. pp. 469-472. ISSN 0007-0920

Brown, J.E., Thomson, C.S., Ellis, S.P. et al. (3 more authors) (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. British Journal of Cancer, 89 (11). pp. 2031-2037. ISSN 0007-0920

Book Section

Wood, S.L., Lopez-Guajardo, A. and Brown, J.E. orcid.org/0000-0003-4960-3032 (2021) Identification of new therapeutic targets of bone cancers by proteomic strategies. In: Heymann, D., (ed.) Bone Sarcomas and Bone Metastases - From Bench to Bedside. Academic Press (Elsevier) , pp. 783-803. ISBN 9780128216668

Proceedings Paper

Brown, J.E. orcid.org/0000-0003-4960-3032, Handforth, C., Walsh, J. orcid.org/0000-0002-7122-2650 et al. (5 more authors) (2019) 857P - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial. In: Annals of Oncology. 44th ESMO Congress (ESMO 2019), 27 Sep - 01 Oct 2019, Barcelona, Spain. Elsevier BV , v334-v335.